×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARQT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
6/11
09:28 pm
arqt
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy? [Yahoo! Finance]
Low
Report
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy? [Yahoo! Finance]
6/9
08:17 pm
arqt
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status [Yahoo! Finance]
6/9
05:28 pm
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript [Seeking Alpha]
6/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/3
08:00 am
arqt
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Low
Report
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
5/26
04:00 pm
arqt
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Low
Report
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
5/15
07:57 am
arqt
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound [Seeking Alpha]
5/9
01:43 am
arqt
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
5/6/2026
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
MISS
Report
-14.5%
arcutis biotherapeutics, inc. - common stock
2/25/2026
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
5.8%
arcutis biotherapeutics, inc. - common stock
10/28/2025
08:30 am
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
18.3%
arcutis biotherapeutics, inc. - common stock
8/6/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
-8.1%
arcutis biotherapeutics, inc. - common stock
Date
Time
Symbol
Headline
Impact
6/12
05:55 pm
arqt
Form 4/A Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J
Medium
Report
Form 4/A Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J
6/9
09:22 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J
6/9
09:21 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Leonard Keith R
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Leonard Keith R
6/9
09:21 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Curran Terrie
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Curran Terrie
6/9
09:21 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: LIN SUE-JEAN
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: LIN SUE-JEAN
6/9
09:21 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Munshi Amit
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Munshi Amit
6/9
09:21 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Welgus Howard G.
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Welgus Howard G.
6/9
09:21 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Krishnamohan Neha
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Krishnamohan Neha
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 10-K Arcutis Biotherapeutics, For: Dec 31
33.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
TOP News Decliners
3/16
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
-16.2%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: